Adverse Outcome Pathways
An adverse outcome pathway (AOP) is structured representation of biological events leading to adverse effects and is considered relevant to risk assessment. The AOP links in a linear way existing knowledge along one or more series of causally connected key events (KE) between two points — a molecular initiating event (MIE) and an adverse outcome (AO) that occur at a level of biological organization relevant to risk assessment. The linkage between the events is described by key event relationships (KER) that describe the causal relationships between the key events. AOPs are important for expanding the use of mechanistic toxicological data for risk assessment and regulatory applications.
- Enzymes
- Anti-Platelet Drugs
- Aspirin
Related Conference of Adverse Outcome Pathways
March 09-10, 2026
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
Singapore City, Singapore
June 18-19, 2026
16th International Conference on Human Genetics and Genetic Diseases
Singapore City, Singapore
June 18-19, 2026
19th International Conference on Genomics & Pharmacogenomics
Singapore City, Singapore
Adverse Outcome Pathways Conference Speakers
Recommended Sessions
- Adverse Outcome Pathways
- Biomarkers in Toxicogenomics
- Cardiovascular Toxicology
- Concept of Toxicogenomics
- Drug monitoring
- Genetic Toxicology
- Genomic Approaches to Predictive Toxicology
- Predictive Human Toxicity and ADME/Tox Studies
- Reproductive and Developmental Toxicology
- Technologies in Toxicogenomics
- Toxicogenomics
- Toxicology study in Haemostasis
- Toxicopathology
Related Journals
Are you interested in
- 3D Bioprinting, Organ Fabrication & Bioartificial Tissues - Stem Cell 2026 (Netherlands)
- Aging Biology, Longevity Science & Cellular Rejuvenation - Stem Cell 2026 (Netherlands)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioinformatics, AI Models & Predictive Regeneration - Stem Cell 2026 (Netherlands)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Stem Cells & Targeted Therapeutics - Stem Cell 2026 (Netherlands)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiac, Vascular & Musculoskeletal Regeneration - Stem Cell 2026 (Netherlands)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Clinical Translation of Stem Cell Therapies - Stem Cell 2026 (Netherlands)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Commercialization, Biobanking & Industry Innovations - Stem Cell 2026 (Netherlands)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Ethical, Regulatory & Quality Control Frameworks - Stem Cell 2026 (Netherlands)
- Exosomes, Extracellular Vesicles & Cell-Free Therapeutics - Stem Cell 2026 (Netherlands)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Gene Editing, CRISPR Therapies & Regenerative Genomics - Stem Cell 2026 (Netherlands)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Regeneration in Neurodegenerative & Spinal Cord Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Approaches in Diabetes & Metabolic Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Immunology & Immune Modulation - Stem Cell 2026 (Netherlands)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Engineering & Cellular Reprogramming - Stem Cell 2026 (Netherlands)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Tissue Engineering, Biomaterials & Smart Scaffolds - Stem Cell 2026 (Netherlands)